Niche retinal therapy Replenish, Inc. targets the $7B retinal therapeutic market with the world's smallest implantable, refillable drug pump, currently in clinical investigation. This presents sales opportunities within ophthalmology-focused biotec devices and potential partnerships with clinics and hospitals performing AMD treatments.

Clinical trial stage The MicroPump is not yet FDA approved and is in clinical investigation. Sales efforts should focus on early-adopter ophthalmology centers, research institutions, and potential collaborators for early access programs, while aligning with regulatory milestones and outcomes.

High-touch physician workflow The device requires a 20-minute outpatient procedure, wireless programming, and semi-annual refills. There is a need for ongoing clinical support, training, and service contracts to ensure smooth integration into physician workflows and patient care pathways.

Limited competitors and scale With a small team and a specialized product, partnerships with larger ophthalmology distributors, academic medical centers, and contract research organizations could amplify reach, while capitalizing on the unique value proposition of reduced administration frequency for biotech therapies.

Growth readiness and funding Current revenue range and a modest funding level indicate readiness for strategic collaborations, pilot programs, and grant-funded initiatives. Opportunities exist to explore co-development deals, testbeds, and pricing models tied to clinical efficacy and patient outcomes.